LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Apolipoprotein CIII Reduction Protects White Adipose Tissues against Obesity-Induced Inflammation and Insulin Resistance in Mice.

    Recio-López, Patricia / Valladolid-Acebes, Ismael / Berggren, Per-Olof / Juntti-Berggren, Lisa

    International journal of molecular sciences

    2021  Volume 23, Issue 1

    Abstract: Apolipoprotein CIII (apoCIII) is proinflammatory and increases in high-fat diet (HFD)-induced obesity and insulin resistance. We have previously shown that reducing apoCIII improves insulin sensitivity in vivo by complex mechanisms involving liver and ... ...

    Abstract Apolipoprotein CIII (apoCIII) is proinflammatory and increases in high-fat diet (HFD)-induced obesity and insulin resistance. We have previously shown that reducing apoCIII improves insulin sensitivity in vivo by complex mechanisms involving liver and brown adipose tissue. In this study the focus was on subcutaneous (SAT) and visceral (VAT) white adipose tissue (WAT). Mice were either given HFD for 14 weeks and directly from start also treated with antisense oligonucleotide (ASO) against apoCIII or given HFD for 10 weeks and HFD+ASO for an additional 14 weeks. Both groups had animals treated with inactive (Scr) ASO as controls and in parallel chow-fed mice were injected with saline. Preventing an increase or lowering apoCIII in the HFD-fed mice decreased adipocytes' size, reduced expression of inflammatory cytokines and increased expression of genes related to thermogenesis and beiging. Isolated adipocytes from both VAT and SAT from the ASO-treated mice had normal insulin-induced inhibition of lipolysis compared to cells from Scr-treated mice. In conclusion, the HFD-induced metabolic derangements in WATs can be prevented and reversed by lowering apoCIII.
    MeSH term(s) Adipocytes/metabolism ; Adipose Tissue, Brown/metabolism ; Adipose Tissue, White/metabolism ; Animals ; Apolipoprotein C-III/metabolism ; Diet, High-Fat ; Inflammation/metabolism ; Insulin/metabolism ; Insulin Resistance/physiology ; Lipolysis/physiology ; Liver/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Obesity/metabolism ; Thermogenesis/physiology
    Chemical Substances Apolipoprotein C-III ; Insulin
    Language English
    Publishing date 2021-12-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23010062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII.

    Recio-López, Patricia / Valladolid-Acebes, Ismael / Hadwiger, Philipp / Hossbach, Markus / Krampert, Monika / Prata, Carla / Berggren, Per-Olof / Juntti-Berggren, Lisa

    BioFactors (Oxford, England)

    2022  Volume 49, Issue 1, Page(s) 153–172

    Abstract: Apolipoprotein CIII (apoCIII) is increased in obesity-induced insulin resistance and type-2 diabetes. Emerging evidences support the advantages of small interfering RNAs (siRNAs) to target disease-causing genes. The aim of this study was to develop ... ...

    Abstract Apolipoprotein CIII (apoCIII) is increased in obesity-induced insulin resistance and type-2 diabetes. Emerging evidences support the advantages of small interfering RNAs (siRNAs) to target disease-causing genes. The aim of this study was to develop siRNAs for in vivo silencing of apoCIII and investigate if this results in metabolic improvements comparable to what we have seen using antisense oligonucelotides against apoCIII. Twenty-four siRNAs were synthesized and tested in a dual luciferase reporter assay. The eight best were selected, based on knockdown at 20 nM, and of these, two were selected based on IC
    MeSH term(s) Mice ; Animals ; Apolipoprotein C-III/genetics ; Apolipoprotein C-III/metabolism ; Apolipoprotein C-III/pharmacology ; Metabolic Syndrome ; RNA, Small Interfering ; Diabetes Mellitus, Type 2 ; Obesity
    Chemical Substances Apolipoprotein C-III ; RNA, Small Interfering
    Language English
    Publishing date 2022-08-30
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 59230-4
    ISSN 1872-8081 ; 0951-6433
    ISSN (online) 1872-8081
    ISSN 0951-6433
    DOI 10.1002/biof.1885
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2473: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: ATF5 is a regulator of ER stress and β-cell apoptosis in different mouse models of genetic- and diet-induced obesity and diabetes mellitus.

    Ma, Jinfang / Liu, Yuqi / Valladolid-Acebes, Ismael / Recio-López, Patricia / Peng, Ge / Li, Juan / Berggren, Per-Olof / Juntti-Berggren, Lisa / Tong, Nanwei

    Cellular signalling

    2022  Volume 102, Page(s) 110535

    Abstract: Endoplasmic reticulum (ER) stress is closely associated with type 2 diabetes (T2D). Activating transcription factor 5 (ATF5) is a member of the ATF/cAMP response element binding protein (CREB) family whose levels are increased upon stress in pancreatic ... ...

    Abstract Endoplasmic reticulum (ER) stress is closely associated with type 2 diabetes (T2D). Activating transcription factor 5 (ATF5) is a member of the ATF/cAMP response element binding protein (CREB) family whose levels are increased upon stress in pancreatic islets from mice. Intriguingly, ATF5 deficiency has been shown to contribute to increased ER stress and apoptosis in mouse islet micro-organs. We hypothesized that either deficiency or overexpression of ATF5 is equally deleterious for pancreatic islets in terms of ER stress and apoptosis. To test this, we used a number of in vitro and in vivo models whereby ATF5 levels were overexpressed. We also determined the regulation of ATF5 in the context of metabolic derangements by using various mouse models of obesity and T2D. Our in vitro results show that ATF5 overexpression promoted palmitic acid (PA)-induced lipotoxic apoptosis. In vivo, global ATF5 overexpression in mice was lethal and pancreas-specific ATF5 overexpressing mice exhibit increased β-cell apoptosis. Interestingly, ATF5 is downregulated in all mouse models of severe obesity and T2D used in the current study. In conclusion, a tight control on ATF5 levels might be considered when developing novel agents targeting ATF5 for prevention and treatment of metabolic diseases.
    MeSH term(s) Mice ; Animals ; Cyclic AMP Response Element-Binding Protein/metabolism ; Activating Transcription Factors/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Apoptosis/physiology ; Disease Models, Animal ; Diet ; Obesity/metabolism ; Insulin-Secreting Cells/metabolism ; Endoplasmic Reticulum Stress/physiology
    Chemical Substances Cyclic AMP Response Element-Binding Protein ; Activating Transcription Factors ; Atf5 protein, mouse
    Language English
    Publishing date 2022-11-24
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1002702-6
    ISSN 1873-3913 ; 0898-6568
    ISSN (online) 1873-3913
    ISSN 0898-6568
    DOI 10.1016/j.cellsig.2022.110535
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2579: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Lowering apolipoprotein CIII protects against high-fat diet-induced metabolic derangements.

    Valladolid-Acebes, Ismael / Åvall, Karin / Recio-López, Patricia / Moruzzi, Noah / Bryzgalova, Galyna / Björnholm, Marie / Krook, Anna / Alonso, Elena Fauste / Ericsson, Madelene / Landfors, Fredrik / Nilsson, Stefan K / Berggren, Per-Olof / Juntti-Berggren, Lisa

    Science advances

    2021  Volume 7, Issue 11

    Abstract: Increased levels of apolipoprotein CIII (apoCIII), a key regulator of lipid metabolism, result in obesity-related metabolic derangements. We investigated mechanistically whether lowering or preventing high-fat diet (HFD)-induced increase in apoCIII ... ...

    Abstract Increased levels of apolipoprotein CIII (apoCIII), a key regulator of lipid metabolism, result in obesity-related metabolic derangements. We investigated mechanistically whether lowering or preventing high-fat diet (HFD)-induced increase in apoCIII protects against the detrimental metabolic consequences. Mice, first fed HFD for 10 weeks and thereafter also given an antisense (ASO) to lower apoCIII, already showed reduced levels of apoCIII and metabolic improvements after 4 weeks, despite maintained obesity. Prolonged ASO treatment reversed the metabolic phenotype due to increased lipase activity and receptor-mediated hepatic uptake of lipids. Fatty acids were transferred to the ketogenic pathway, and ketones were used in brown adipose tissue (BAT). This resulted in no fat accumulation and preserved morphology and function of liver and BAT. If ASO treatment started simultaneously with the HFD, mice remained lean and metabolically healthy. Thus, lowering apoCIII protects against and reverses the HFD-induced metabolic phenotype by promoting physiological insulin sensitivity.
    MeSH term(s) Adipose Tissue, Brown/metabolism ; Animals ; Apolipoprotein C-III/metabolism ; Diet, High-Fat/adverse effects ; Metabolic Diseases/metabolism ; Mice ; Mice, Inbred C57BL ; Obesity/etiology ; Obesity/metabolism ; Obesity/prevention & control
    Chemical Substances Apolipoprotein C-III
    Language English
    Publishing date 2021-03-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2810933-8
    ISSN 2375-2548 ; 2375-2548
    ISSN (online) 2375-2548
    ISSN 2375-2548
    DOI 10.1126/sciadv.abc2931
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top